Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT

S. Masouridi-Levrat*, E. Olavarria, S. Iacobelli, M. Aljurf, E. Morozova, R. Niittyvuopio, H. Sengeloev, P. Remenyi, G. Helbig, P. Browne, A. Ganser, A. Nagler, J.A. Snowden, M. Robin, J. Passweg, G. Van Gorkom, H.L. Wallet, J. Hoek, H.J. Blok, T. De WitteN. Kroeger, P. Hayden, Y. Chalandon, I.Y. Agha

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Number of pages8
JournalBone Marrow Transplantation
DOIs
Publication statusE-pub ahead of print - 1 Oct 2021

Keywords

  • CHRONIC MYELOGENOUS LEUKEMIA
  • CHRONIC-PHASE
  • IMATINIB MESYLATE
  • PROGNOSTIC-FACTORS
  • ADVANCED DISEASE
  • FOLLOW-UP
  • DASATINIB
  • NILOTINIB
  • CML
  • THERAPY

Cite this